Humacyte, Inc. (NASDAQ:HUMAW) Short Interest Update

Humacyte, Inc. (NASDAQ:HUMAW) was the target of a large decline in short interest in July. As of July 15th, there was short interest totaling 3,752 shares, a decline of 84.7% from the June 30th total of 24,488 shares. Based on an average daily volume of 15,476 shares, the short-interest ratio is presently 0.2 days.

Humacyte Stock Up 1.0%

HUMAW traded up $0.00 on Friday, reaching $0.01. 11,661 shares of the company’s stock were exchanged, compared to its average volume of 17,359. The company’s 50 day moving average is $0.03 and its 200-day moving average is $0.08. Humacyte has a twelve month low of $0.00 and a twelve month high of $0.58.

Humacyte Company Profile

Humacyte, Inc (NASDAQ:HUMAW) is a clinical-stage biotechnology company specializing in the development and manufacture of human acellular vessels (HAVs). These off-the-shelf, bioengineered vascular conduits are designed to serve as living implants for patients requiring vascular access, including those undergoing hemodialysis, as well as for peripheral artery disease and vascular trauma. Humacyte’s proprietary tissue-engineering platform leverages human vascular cells cultured on biodegradable scaffolds, which are subsequently decellularized to produce durable, non-immunogenic vessels that support natural tissue regeneration.

Founded in 2007 and headquartered in Durham, North Carolina, Humacyte has advanced its lead candidate, the HAV, through multiple clinical trials in the United States and Europe.